Matches in Wikidata for { <http://www.wikidata.org/entity/Q91355917> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- Q91355917 description "article scientifique publié en 2019" @default.
- Q91355917 description "artículu científicu espublizáu en payares de 2019" @default.
- Q91355917 description "scientific article published on 01 November 2019" @default.
- Q91355917 description "wetenschappelijk artikel" @default.
- Q91355917 description "наукова стаття, опублікована 1 листопада 2019" @default.
- Q91355917 description "գիտական հոդված հրատարակված 2019 թվականի նոյեմբերի 1-ին" @default.
- Q91355917 name "Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial" @default.
- Q91355917 name "Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial" @default.
- Q91355917 type Item @default.
- Q91355917 label "Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial" @default.
- Q91355917 label "Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial" @default.
- Q91355917 prefLabel "Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial" @default.
- Q91355917 prefLabel "Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial" @default.
- Q91355917 P1433 Q91355917-672BE0C7-2902-4E9C-B629-199E9A08B85A @default.
- Q91355917 P1476 Q91355917-B9811192-4268-475D-B7AC-A814FD680817 @default.
- Q91355917 P2093 Q91355917-18A77A59-6631-4547-B571-0D26DCCB1F41 @default.
- Q91355917 P2093 Q91355917-23BED88F-3383-47E1-A4A3-8BDEA0FFEE2B @default.
- Q91355917 P2093 Q91355917-461FC77F-022B-4242-9CD0-F8CCFDE2932D @default.
- Q91355917 P2093 Q91355917-56AFC631-2AA3-45DE-99B9-5072CCE2F2DF @default.
- Q91355917 P2093 Q91355917-85BAF7E7-F834-4C86-96A0-4D3721FCEFD7 @default.
- Q91355917 P2093 Q91355917-8661E915-0D7E-4789-8E67-1BBB05CF7204 @default.
- Q91355917 P2093 Q91355917-91D79AE5-5016-4A4D-98A0-559437C55D01 @default.
- Q91355917 P2093 Q91355917-98B82B26-78AE-4FCD-9002-C3FA5C9084D8 @default.
- Q91355917 P2093 Q91355917-B087A0E3-70C2-45D4-AC05-4CACEE639F32 @default.
- Q91355917 P2093 Q91355917-D44F43A0-537F-43C3-AE79-5405100E6D93 @default.
- Q91355917 P275 Q91355917-b0d6ea73-e724-49cb-8249-ed1da9a8a931 @default.
- Q91355917 P304 Q91355917-18023733-3B63-43FA-8CB5-DA33C405D6C9 @default.
- Q91355917 P31 Q91355917-4A00ED43-824C-4F28-BF21-5BFB14A58AB8 @default.
- Q91355917 P356 Q91355917-02020AA1-C011-4023-8B66-D8F980EE107B @default.
- Q91355917 P433 Q91355917-E96F601B-6DA2-4055-914A-1F53214B2FED @default.
- Q91355917 P478 Q91355917-A458FD17-AD15-4DD9-94A2-DB0EE99437DC @default.
- Q91355917 P50 Q91355917-3E489F46-8D6B-47C2-A93C-AF6FA58C9834 @default.
- Q91355917 P577 Q91355917-58CFEC4E-A3AE-4637-B897-9601E8CCFCB5 @default.
- Q91355917 P6216 Q91355917-80b19fd7-c53d-4db3-be4b-b7ccabbd3d54 @default.
- Q91355917 P698 Q91355917-C7B032CC-0448-42A2-8B63-D9118A320F2A @default.
- Q91355917 P921 Q91355917-10B5187C-DB4E-443B-8317-FEDFE9F9B0E7 @default.
- Q91355917 P921 Q91355917-1461FFC3-9C03-4C9A-A433-C067D870D070 @default.
- Q91355917 P932 Q91355917-A5744B30-F4C0-40ED-A72F-2AFD18B1F70D @default.
- Q91355917 P356 CIZ090 @default.
- Q91355917 P698 30722059 @default.
- Q91355917 P1433 Q5133764 @default.
- Q91355917 P1476 "Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial" @default.
- Q91355917 P2093 "Anita Das" @default.
- Q91355917 P2093 "Carolyn Sweeney" @default.
- Q91355917 P2093 "Elyse Seltzer" @default.
- Q91355917 P2093 "George H Talbot" @default.
- Q91355917 P2093 "John Saviski" @default.
- Q91355917 P2093 "Leanne B Gasink" @default.
- Q91355917 P2093 "Lisa Goldberg" @default.
- Q91355917 P2093 "Steven P Gelone" @default.
- Q91355917 P2093 "Susanne Paukner" @default.
- Q91355917 P2093 "Wolfgang W Wicha" @default.
- Q91355917 P275 Q34179348 @default.
- Q91355917 P304 "1856-1867" @default.
- Q91355917 P31 Q13442814 @default.
- Q91355917 P356 "10.1093/CID/CIZ090" @default.
- Q91355917 P433 "11" @default.
- Q91355917 P478 "69" @default.
- Q91355917 P50 Q124419900 @default.
- Q91355917 P577 "2019-11-01T00:00:00Z" @default.
- Q91355917 P6216 Q50423863 @default.
- Q91355917 P698 "30722059" @default.
- Q91355917 P921 Q3776920 @default.
- Q91355917 P921 Q42824827 @default.
- Q91355917 P932 "6853694" @default.